Open Access

SGLT-2 Inhibitors in Heart Failure: Where are we now and where are we heading?

Topic: Chronic Heart Failure
Organised by Radcliffe Medical Education - Supported by an unrestricted educational grant from the Boehringer Ingelheim & Lilly Alliance

Congress Session

About the speaker

Professor Andrew Coats

University of Warwick, Coventry (United Kingdom of Great Britain & Northern Ireland)
95 presentations
10 followers

5 more presentations in this session

Summary of how the Tx paradigm for HF has changed.

Speaker: Professor B. Bozkurt (Houston, US)

Thumbnail

Unanswered Questions.

Speaker: Professor A. Coats (Coventry, GB) Professor B. Bozkurt (Houston, US) Professor C. Lam (Singapore, SG)

Thumbnail

Best practice of SGLT-2 inhibitors in HFrEF: What constitutes best practice today?

Speaker: Professor C. Lam (Singapore, SG)

Thumbnail

Implementation in Practice: What are the Practical Considerations?

Speaker: Professor A. Coats (Coventry, GB) Professor C. Lam (Singapore, SG) Professor B. Bozkurt (Houston, US)

Thumbnail

Q&A.

Speaker: Professor A. Coats (Coventry, GB) Professor B. Bozkurt (Houston, US) Professor C. Lam (Singapore, SG)

Thumbnail

Access the full session

A Changing Paradigm: Defining the Future Role of SGLT-2 Inhibitors

Speakers: Professor A. Coats, Professor B. Bozkurt, Professor A. Coats, Professor B. Bozkurt, Professor C. Lam...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ACVC Premium Access

Proposed treatment after TTM2.

18 March 2022

ACVC Premium Access

TTM2: a game changer?

18 March 2022

ACVC Premium Access

Clinical trial evidence.

18 March 2022

This platform is supported by

logo Novo Nordisk